Fanconi syndrome primary prevention: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Primary Prevention==
==Primary Prevention==
Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome's progression or even onset:
Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome's progression or even onset<ref name="pmid24076416">{{cite journal| author=Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R et al.| title=Long-term outcomes of patients with Wilson disease in a large Austrian cohort. | journal=Clin Gastroenterol Hepatol | year= 2014 | volume= 12 | issue= 4 | pages= 683-9 | pmid=24076416 | doi=10.1016/j.cgh.2013.09.025 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24076416  }}</ref>:
* Cystinosis medical therapy
* [[Cystinosis]] medical therapy
* Wilson disease medical therapy
* [[Wilson's disease|Wilson disease]] medical therapy
* [[Tyrosinemia]] medical therapy


Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome's progression or even onset:
Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome's progression or even onset:
* Galactosemia, Galctose consumption restriction
* [[Galactosemia]], Galctose consumption restriction
* Hereditary fructose intolerance, Fructose consumption restriction
* [[Hereditary fructose intolerance]], Fructose consumption restriction
* Tyrosinemia, tyrosine/phenylalanine consumption restriction
* [[Tyrosinemia]], tyrosine/phenylalanine consumption restriction
* Any precipitating drug or heavy metal exposure restriction or adjustment, including: ''Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides and tetracyclines''
* Any precipitating drug or heavy metal exposure restriction or adjustment, including: ''Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides, tetracyclines, cadmium and lead''





Revision as of 07:07, 17 June 2018

Fanconi syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fanconi syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study Of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fanconi syndrome primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fanconi syndrome primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fanconi syndrome primary prevention

CDC on Fanconi syndrome primary prevention

Fanconi syndrome primary prevention in the news

Blogs on Fanconi syndrome primary prevention

Directions to Hospitals Treating Fanconi syndrome

Risk calculators and risk factors for Fanconi syndrome primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Prevention of Fanconi syndrome mostly depends on early diagnosis, treatment and management of potential underlying diseases and/or preventing the toxicity of the exposure to exogenous precipitating factors.

Primary Prevention

Diagnosis, treatment and management of these potential underlying diseases in their early stages may prevent Fanconi syndrome's progression or even onset[1]:

Preventing the toxicity of the exposure to exogenous precipitating factors may prevent Fanconi syndrome's progression or even onset:

  • Galactosemia, Galctose consumption restriction
  • Hereditary fructose intolerance, Fructose consumption restriction
  • Tyrosinemia, tyrosine/phenylalanine consumption restriction
  • Any precipitating drug or heavy metal exposure restriction or adjustment, including: Nucleoside Reverse Transcriptase Inhibitors, Valproic acid, Aminoglycosides, tetracyclines, cadmium and lead


References

  1. Beinhardt S, Leiss W, Stättermayer AF, Graziadei I, Zoller H, Stauber R; et al. (2014). "Long-term outcomes of patients with Wilson disease in a large Austrian cohort". Clin Gastroenterol Hepatol. 12 (4): 683–9. doi:10.1016/j.cgh.2013.09.025. PMID 24076416.

Template:WH Template:WS